In this interesting article entitled “A Faster, More Cost-Effective Alternative to Generic Bioequivalence”, Dr. Jag Shur, CEO of Nanopharm, an Aptar Pharma company, explores the challenges companies face in bringing generic respiratory and nasal therapies to market amidst a changing regulatory landscape. He explains the Aptar Pharma Services range for accelerating and derisking OINDP development, and introduces the CPhI 2019 Award winning SmartTrack™ as an alternative to bioequivalence studies.
